Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, March 24, 2023
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Thursday, March 23, 2023
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Monday, March 20, 2023
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
Tuesday, March 14, 2023
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
Friday, March 10, 2023
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
Thursday, March 9, 2023
Eisai Certified as a 2023 Health and Productivity Management Outstanding
Monday, March 6, 2023
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Thursday, March 2, 2023
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
Tuesday, February 28, 2023
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Tuesday, February 21, 2023
Dissolution of Bracco-Eisai Joint Venture

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: